» Articles » PMID: 35930450

Suspected Interstitial Lung Disease in COPDGene Study

Abstract

Although interstitial lung abnormalities (ILA), specific patterns of incidentally-detected abnormal density on computed tomography, have been associated with abnormal lung function and increased mortality, it is unclear if a subset with incidental interstitial lung disease (ILD) accounts for these adverse consequences. To define the prevalence and risk factors of suspected ILD and assess outcomes. Suspected ILD was evaluated in the COPDGene (Chronic Obstructive Pulmonary Disease Genetic Epidemiology) study, defined as ILA and at least one additional criterion: definite fibrosis on computed tomography, FVC less than 80% predicted, or DL less than 70% predicted. Multivariable linear, longitudinal, and Cox proportional hazards regression models were used to assess associations with St. George's Respiratory Questionnaire, 6-minute-walk test, supplemental oxygen use, respiratory exacerbations, and mortality. Of 4,361 participants with available data, 239 (5%) had evidence for suspected ILD, whereas 204 (5%) had ILA without suspected ILD. In multivariable analyses, suspected ILD was associated with increased St. George's Respiratory Questionnaire score (mean difference [MD], 3.9 points; 95% confidence interval [CI], 0.6-7.1;  = 0.02), reduced 6-minute-walk test (MD, -35 m; 95% CI, -56 m to -13 m;  = 0.002), greater supplemental oxygen use (odds ratio [OR], 2.3; 95% CI, 1.1-5.1;  = 0.03) and severe respiratory exacerbations (OR, 2.9; 95% CI, 1.1-7.5;  = 0.03), and higher mortality (hazard ratio, 2.4; 95% CI, 1.2-4.6;  = 0.01) compared with ILA without suspected ILD. Risk factors associated with suspected ILD included self-identified Black race (OR, 2.0; 95% CI, 1.1-3.3;  = 0.01) and pack-years smoking history (OR, 1.2; 95% CI, 1.1-1.3;  = 0.0005). Suspected ILD is present in half of those with ILA in COPDGene and is associated with exercise decrements and increased symptoms, supplemental oxygen use, severe respiratory exacerbations, and mortality.

Citing Articles

Interstitial Lung Abnormalities: Unraveling the Journey from Incidental Discovery to Clinical Significance.

Gogali A, Kyriakopoulos C, Kostikas K Diagnostics (Basel). 2025; 15(4).

PMID: 40002659 PMC: 11854474. DOI: 10.3390/diagnostics15040509.


Prevalence and clinical features of interstitial lung disease in patients with psoriasis.

Kanaji N, Misaki N, Murota M, Iwata M, Ishikawa R, Yamamura K BMC Pulm Med. 2024; 24(1):610.

PMID: 39695614 PMC: 11657358. DOI: 10.1186/s12890-024-03450-7.


Long-Term Follow-Up of Interstitial Lung Abnormalities in Low-Dose Chest CT in Health Screening: Exploring the Predictors of Clinically Significant Interstitial Lung Diseases Using Artificial Intelligence-Based Quantitative CT Analysis.

Jeong W, Nam B, Hwang J, Lee C, Yoon H, Lee E J Korean Soc Radiol. 2024; 85(6):1141-1156.

PMID: 39660324 PMC: 11625842. DOI: 10.3348/jksr.2024.0032.


Big Things Have Small Beginnings: Clinical Implications of Early Interstitial Lung Disease.

Podolanczuk A, Tomassetti S Am J Respir Crit Care Med. 2024; 210(12):1394-1395.

PMID: 39312209 PMC: 11716032. DOI: 10.1164/rccm.202408-1611ED.


Development, Progression, and Mortality of Suspected Interstitial Lung Disease in COPDGene.

Rose J, Tukpah A, Cutting C, Wada N, Nishino M, Moll M Am J Respir Crit Care Med. 2024; 210(12):1453-1460.

PMID: 39133466 PMC: 11716042. DOI: 10.1164/rccm.202402-0313OC.


References
1.
Hunninghake G, Quesada-Arias L, Carmichael N, Martinez Manzano J, Poli de Frias S, Alvarez Baumgartner M . Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis. Am J Respir Crit Care Med. 2020; 201(10):1240-1248. PMC: 7233344. DOI: 10.1164/rccm.201908-1571OC. View

2.
Doyle T, Hunninghake G, Rosas I . Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012; 185(11):1147-53. PMC: 3373068. DOI: 10.1164/rccm.201108-1420PP. View

3.
Curry S, Krist A, Owens D, Barry M, Caughey A, Davidson K . Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 319(24):2521-2531. DOI: 10.1001/jama.2018.7498. View

4.
Araki T, Putman R, Hatabu H, Gao W, Dupuis J, Latourelle J . Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016; 194(12):1514-1522. PMC: 5215030. DOI: 10.1164/rccm.201512-2523OC. View

5.
Hunninghake G . Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax. 2019; 74(5):506-511. PMC: 6475107. DOI: 10.1136/thoraxjnl-2018-212446. View